Sharing the Sights of BioMedical and Pharmaceutical Domains on Demo-DVD

CAST PHARMACAST PHARMA, a premier European 3D pharmaceutical and biomedical animation production company, is pleased to announce the availability of an advanced Demo-DVD to make its audiovisual material more widely available to the existing and further customers from the biomedical and pharmaceutical domains.

"This initiative reflects the CAST PHARMA's commitment to better explain and share its realizations and achievements on advanced and scientifically accurate 3D animation techniques - such as "mode of action" at the molecular, cellular, tissue or organ levels," said Mr. Stefan Wolf, CAST PHARMA owner.

Pharma marketing, brand and product professionals can explore the latest CAST PHARMA's 3D videos, on a wide-range of topics: Immunology, Respiratory Tract, Dermatology, Endocrinology, Gastroenterology, Cardiovascular, Ophthalmology, Neurology/Pain, etc. All videos are available on a promotional DVD with an easy and intuitive interface.

"It is very important for us to use all the means at our disposal when it comes to enhancing our communication capabilities with our current and further customers," explained Mr. Stefan Wolf.

With the extended capabilities of its Demo-DVD, CAST PHARMA will focus on promoting its advanced 3 D visualization techniques and services. By announcing the DVD, CAST PHARMA has confirmed its leading position as an advanced and highly professional 3D animations production company.

"We encourage pharmaceutical professionals to request our Demo-DVD, available free of charge, from CAST PHARMA web page. DVD content would serve as example of how our customers are promoting their messages and differentiate themselves from their competitors with scientifically accurate and visually compelling 3D animations," concluded Mr. Wolf.

For further information, please visit:

About CAST PHARMA
CAST PHARMA is a premier European 3D pharmaceutical and biomedical animation production company. For more information, please visit www.cast-pharma.com.

Most Popular Now

COVID-19 can trigger self-attacking antibodies

Infection with the virus that causes COVID-19 can trigger an immune response that lasts well beyond the initial infection and recovery - even among people who had mild sy...

Stopping dementia at the nose with combination of …

Dementia is thought to occur when proteins called amyloid-β, tau, and α-synuclein accumulate in the brain and form oligomers. A research group from the Department of Tran...

Treatments in weeks, not months: Scientists develo…

An international team of scientists has created a plan for an accelerated pipeline for developing drug cocktails to battle the COVID-19 pandemic. The pipeline could speed...

COVID-19 - Omicron: resistant to most monoclonal a…

The Omicron variant was detected for the first time in South Africa in November 2021 and has since spread to many countries. It is expected to become the dominant variant...

Scientists identify antibodies that can neutralize…

An international team of scientists have identified antibodies that neutralize omicron and other SARS-CoV-2 variants. These antibodies target areas of the virus spike pro...

Pfizer and BioNTech sign new global collaboration …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a new research, development and commercialization collaboration to develop a potential first mRNA-based v...

Novartis and Molecular Partners report positive to…

Novartis and Molecular Partners announced that Part A of the EMPATHY clinical trial(1) that compared single intravenous doses of ensovibep, a DARPin antiviral therapeutic...

Bayer and Mammoth Biosciences to collaborate on no…

Bayer AG and Mammoth Biosciences, Inc., which is harnessing the diversity of nature to power the next-generation CRISPR products, today announced a strategic collaboratio...

Amgen and Arrakis Therapeutics announce multi-targ…

Amgen (NASDAQ:AMGN) and Arrakis Therapeutics today announced a research collaboration focused on the discovery and development of RNA degrader therapeutics against a rang...

Leiden University Medical Center and Intravacc to …

Intravacc, a global leader in translational research and development of therapeutic vaccines and vaccines against infectious diseases, today announced a partnership with ...

New Vaxzevria data further support its use as thir…

Positive results from a preliminary analysis of an ongoing safety and immunogenicity trial (D7220C00001) showed that Vaxzevria (ChAdOx1-S [Recombinant]), when given as a ...

AstraZeneca and Ionis close agreement to develop a…

AstraZeneca has closed a global development and commercialisation agreement with Ionis Pharmaceuticals, Inc. (Ionis) for eplontersen, formerly known as IONIS-TTR-LRX. ...